Svb Leerink Comments on Zai Lab Ltd’s FY2019 Earnings (NASDAQ:ZLAB)
Zai Lab Ltd (NASDAQ:ZLAB) – Equities research analysts at Svb Leerink decreased their FY2019 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, June 11th. Svb Leerink analyst J. Chang now anticipates that the company will post earnings per share of ($1.51) for the year, down from their previous forecast of ($1.40). Svb Leerink also issued estimates for Zai Lab’s FY2020 earnings at ($0.42) EPS.
ZLAB has been the subject of a number of other reports. BidaskClub raised Zai Lab from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Zacks Investment Research downgraded Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, April 20th. Finally, Leerink Swann set a $46.00 price objective on Zai Lab and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $36.90.
A number of hedge funds have recently bought and sold shares of ZLAB. Vanguard Group Inc. purchased a new stake in Zai Lab during the third quarter worth approximately $14,955,000. Bank of Montreal Can lifted its stake in Zai Lab by 18.5% during the fourth quarter. Bank of Montreal Can now owns 9,692 shares of the company’s stock worth $225,000 after purchasing an additional 1,512 shares during the last quarter. Tree Line Advisors Hong Kong Ltd. purchased a new stake in Zai Lab during the fourth quarter worth approximately $9,752,000. Matthews International Capital Management LLC purchased a new stake in Zai Lab during the fourth quarter worth approximately $270,000. Finally, California Public Employees Retirement System lifted its stake in Zai Lab by 15.7% during the fourth quarter. California Public Employees Retirement System now owns 32,273 shares of the company’s stock worth $749,000 after purchasing an additional 4,372 shares during the last quarter. Hedge funds and other institutional investors own 36.39% of the company’s stock.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Recommended Story: What does a bar chart mean for investors?
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.